CONMED Corporation, also known by its stock ticker CNMD, is a global medical technology company that specializes in the design and production of surgical devices and equipment for minimally invasive procedures. Established in 1970, the company operates through a shared corporate vision of improving patient outcomes and delivering outstanding quality products and services to healthcare professionals and patients worldwide. Its headquarters is located in Utica, New York, and it operates internationally with direct sales and distributors in over 20 countries.
The company is organized into two main operating units. The Orthopedic Surgery unit focuses on the development and marketing of sports medicine, powered instruments and related products for orthopedic surgeons to repair soft tissue and bone, enable less invasive surgery, and improve patient outcomes. This business unit has pioneered technology across a broad range of clinical areas from arthroscopy, powered surgical instruments, electro-surgery, to patient care, and has driven a series of technological advancements throughout its history.
The second operating unit, General Surgery, is specialized in delivering technologically innovative products that enhance clinical outcomes for patients undergoing gastroenterology procedures, including electrosurgery, endomechanical instrumentation, imaging, and video systems. The growth in this business unit is derived from the ongoing development of innovative and differentiated products, as well as the increasing worldwide prevalence of diseases, like cancer, which require surgical interventions.
Moreover, CONMED Corporation has a strong history of investments in research and development. This is to ensure a robust pipeline of innovative products suited for the evolving needs of surgeons and patients. The company's R&D direction is led by a deep understanding of clinical needs, changes in the healthcare industry, and emerging technology trends.
Listed on NYSE under the symbol "CNMD", the company's robust financial performance is reflective of its consistent focus on relevant product innovation, growing international presence, and operational enhancements. Its leadership in the medical technology space has been marked by the consistent delivery of high-quality products for surgical and patient care and an exemplary performance in meeting global healthcare needs.
In essence, CONMED Corporation marks a distinct presence in the medical technology world through its relentless commitment to improving healthcare. Its significant contributions to minimally invasive surgeries and patient outcomes bear testimony to its focus on innovation and drive for quality products and services. Through its dedication to excellence, CONMED has positioned itself as a leader in medical technology, and a trusted partner to healthcare professionals worldwide.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Argus has lowered its target price for CONMED Corporation (CNMD) to $48.00, citing the medical equipment company's focus on sports medicine and general surgeries. The current stock price for CNMD is $45.18. The report, published on September 23, 2026, provides a summary of the company's business activities.
Bank of America Corp DE has acquired a new stake of 1,341,409 shares in CONMED Corporation, valued at approximately $43.9 million, giving it a 4.48% ownership. Despite this significant investment, analyst sentiment remains cautious with a consensus "Reduce" rating and a price target of $41.40 for CONMED. The medical technology company recently exceeded quarterly expectations with EPS of $1.38 and revenue of $343.5 million, though its stock opened down 1.3% at $44.84.
This article provides an in-depth quantitative analysis of Conmed Corp. (NASDAQ: CNMD), highlighting a neutral near-term sentiment with potential for moderate mid-term weakness. It identifies an exceptional short setup with a 48.6:1 risk-reward ratio, targeting a 14.2% downside. The analysis offers three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, along with multi-timeframe signal analysis.
CONMED Corporation (NYSE:CNMD) has received an average "Reduce" rating from eight analysts, with two recommending "sell" and six "hold." Despite exceeding quarterly earnings expectations with an EPS of $1.38 and revenue of $343.49 million, the average 12-month price target is $41.40, below its current share price of $46.15. Institutional investors like BlackRock and Bank of America have recently increased their positions in the company, while the California State Teachers’ Retirement System significantly boosted its stake.
CONMED Corp (NASDAQ:CNMD) director Kim Kelderman was granted 500 restricted stock units (RSUs) on September 8, 2026, as part of the company's 2025 Long-Term Incentive Plan. The RSUs, acquired at a $0 price, vest 100% after one year, bringing Kelderman's direct ownership to 500 common shares. This transaction was reported in a Form 4 filing on September 10, 2026.
Bank of New York Mellon Corp has acquired 291,203 shares of CONMED Corporation (NYSE:CNMD), valued at approximately $9.5 million, representing about 0.97% of the company. Other institutional investors like AQR Capital Management and Intech Investment Management also increased their stakes, while Creative Planning initiated a new position. Despite CONMED beating quarterly earnings estimates with $1.38 EPS and $343.5 million in revenue, analysts maintain a "Reduce" rating with a consensus price target of $41.40.
BlackRock Inc. has invested approximately $157.78 million in CONMED Corporation, acquiring 4.82 million shares and taking a 16.1% stake in the medical technology company. This investment comes as CONMED exceeded its quarterly earnings expectations, reporting adjusted EPS of $1.38 and revenue of $343.5 million, and provides a fiscal 2026 EPS guidance of $4.48–$4.60. Despite this significant institutional interest, analyst sentiment remains cautious, with a consensus "Reduce" rating and a target price of $41.40.